Decreased messenger RNA expression of key markers of the nigrostriatal dopaminergic system following vitamin E deficiency in the rat

Neuroscience

Volumn 101, Issue 4, 2000, Pages 1029-1036

  Romero Ramos, M ^a   Venero, J L ^a   Santiago, M ^a   Rodriguez Gomez J A ^a   Vizuete, M L ^a   Cano, J ^a   Machado, A ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Dopaminergic system; Free radicals; Substantia nigra; Tyrosine hydroxylase

Indexed keywords

DOPAMINE TRANSPORTER; FREE RADICAL; MESSENGER RNA; TYROSINE 3 MONOOXYGENASE;

ALPHA TOCOPHEROL DEFICIENCY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; FEMALE; GENE EXPRESSION; HISTOCHEMISTRY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; CARRIER PROTEINS; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MESENCEPHALON; NERVE TISSUE PROTEINS; OXIDATION-REDUCTION; RATS; RATS, WISTAR; RNA, MESSENGER; SUBSTANTIA NIGRA; TIME FACTORS; TYROSINE 3-MONOOXYGENASE; VITAMIN E DEFICIENCY;

EID: 0034736187     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(00)00424-3     Document Type: Article

References (41)

1. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death
2. Vitamin E as an in vitro and in vivo antioxidant
3. Effect of a short period of vitamin E deficient diet in the turnover of different neurotransmitters in substantia nigra and striatum of the rat
4. The role of neuronal growth factors in neurodegenerative disorders of the human brain
5. Nigral dopaminergic cell loss in vitamin E deficient rats
6. Nigrostriatal function in vitamin E deficiency: clinical, experimental and PET studies
7. Phenotypical characterisation of neurons expressing the dopamine D3 receptor in the rat brain
8. Development of paralysis in the suckling young mothers deprived of vitamin E
9. Complete code sequence of a rat tyrosine hydroxylase mRNA
10. Reactive oxygen species and the central nervous system
11. Oxidative stress and the pathogenesis of Parkinson's disease
12. 4
13. Determination of carbonyl groups in oxidatively modified proteins by reduction with tritiated sodium borohydride
14. Determination of carbonyl content in oxidatively modified proteins
15. Drug trial for Parkinson's
16. Monoamime metabolism provides an antioxidant defense in the brain against oxidant- and free radical-induced damage
17. Protein measurement with the Folin phenol reagent
18. New developments in understanding the etiology of Parkinson's disease and its treatment
19. The first two decades of vitamin E
20. Vitamin E and neurological function
21. Differential regulation of brain-derived neurotrophic factor and type II calcium/calmodulin-dependent protein kinase messenger RNA expression in Alzheimer's disease
22. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease
23. Combined in situ hybridisation and immunocytochemistry in the assay of the pharmacological effects on tyrosine hydroxylase mRNA concentration
24. Chronic lesions differentially decrease tyrosine hydroxylase messenger RNA in dopaminergic neurons of the substantia nigra
25. Slow changes of tyrosine hydroxylase gene expression in dopaminergic brain neurons after neurotoxin lesioning: a model for neuron aging
26. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease
27. 3H)tyrosine by charcoal
28. Deprenyl induces the tyrosine hydroxylase enzyme in the rat dopaminergic nigrostriatal system
29. A progressive neurologic syndrome with chronic liver disease
30. Oxidative stress in neurodegenerative disease
31. Demyelinating central nervous system disease, macular atrophy and acanthocytosis (Bassen-Kornzweig syndrome)
32. Vitamin E and neurologic function in man
33. Free radicals in medicine. II: Involvement in human disease
34. Metal-ion catalyzed oxidation of protein biochemical mechanism and biological consequences
35. Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy
36. Intrastriatal quinolinic acid injections protect against 6-hydroxydopamine-induced lesions of the dopaminergic nigrostriatal system
37. Time course changes in the dopaminergic nigrostriatal system following transection of the medial forebrain bundle: detection of oxidatively modified proteins in substantia nigra
38. Involvement of free radicals in dementia of Alzheimer type: a hypothesis
39. Differential spatial and temporal gene expression in response to axotomy and deafferation of the medial forebrain bundle
40. Axotomy induced differential gene induction in neurons of the locus coeruleus and substantia nigra